ADAG Quote, Financials, Valuation and Earnings

China Pharma Holding has a net margin of -- compared to Adagene's net margin of -101.61%. Adagene's return on equity of -- beat China Pharma Holding's return on equity of -66.27%.

Adagene has a consensus price target of --, signalling upside risk potential of 293.51%. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Adagene has higher upside potential than China Pharma Holding, analysts believe Adagene is more attractive than China Pharma Holding.

Adagene has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.874%.

Adagene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

Adagene quarterly revenues are --, which are smaller than China Pharma Holding quarterly revenues of $1.1M. Adagene's net income of -- is lower than China Pharma Holding's net income of -$1.1M. Notably, Adagene's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene is 4.96x versus 0.45x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

LakeShore Biopharma has a net margin of -- compared to Adagene's net margin of --. Adagene's return on equity of -- beat LakeShore Biopharma's return on equity of -7.94%.

Adagene has a consensus price target of --, signalling upside risk potential of 293.51%. On the other hand LakeShore Biopharma has an analysts' consensus of -- which suggests that it could grow by 964.57%. Given that LakeShore Biopharma has higher upside potential than Adagene, analysts believe LakeShore Biopharma is more attractive than Adagene.

Adagene has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LakeShore Biopharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Adagene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LakeShore Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene pays -- of its earnings as a dividend. LakeShore Biopharma pays out -- of its earnings as a dividend.

Adagene quarterly revenues are --, which are smaller than LakeShore Biopharma quarterly revenues of --. Adagene's net income of -- is lower than LakeShore Biopharma's net income of --. Notably, Adagene's price-to-earnings ratio is -- while LakeShore Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene is 4.96x versus 0.47x for LakeShore Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -- compared to Adagene's net margin of --. Adagene's return on equity of -- beat Sinovac Biotech's return on equity of -1.05%.

Adagene has a consensus price target of --, signalling upside risk potential of 293.51%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that Adagene has higher upside potential than Sinovac Biotech, analysts believe Adagene is more attractive than Sinovac Biotech.

Adagene has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Adagene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

Adagene quarterly revenues are --, which are smaller than Sinovac Biotech quarterly revenues of --. Adagene's net income of -- is lower than Sinovac Biotech's net income of --. Notably, Adagene's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene is 4.96x versus 1.50x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -- compared to Adagene's net margin of -40.75%. Adagene's return on equity of -- beat Zai Lab's return on equity of -35.53%.

Adagene has a consensus price target of --, signalling upside risk potential of 293.51%. On the other hand Zai Lab has an analysts' consensus of $52.39 which suggests that it could grow by 95.93%. Given that Adagene has higher upside potential than Zai Lab, analysts believe Adagene is more attractive than Zai Lab.

Adagene has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.054%.

Adagene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

Adagene quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $102.3M. Adagene's net income of -- is lower than Zai Lab's net income of -$41.7M. Notably, Adagene's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene is 4.96x versus 7.33x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.